Annals of Medicine and Surgery最新文献

{"title":"Prevalence, causes, and predictors of 30-day readmissions after acute myocardial infarction with ventricular arrhythmias: a cohort study using the 2016-2017 national readmissions database.","authors":"Adarsh Raja, Muhammad Umer Sohail, Muhammad Ans, Saad Ahmed, Ahsan Feroze, Manaal Ashar, Kehan Ali Rizvi, Muhammad Huzaifa Ahmed Khan, Sara Rahman, Muhammad Umer Hayat, Noor Ul Ain, Laraib Kamran, Fnu Pirih, Muhammad Bilal Liaqat, Laksh Kumar, Sumet Kumar, Aayush Chaulagain","doi":"10.1097/MS9.0000000000005534","DOIUrl":"https://doi.org/10.1097/MS9.0000000000005534","url":null,"abstract":"<p><strong>Background: </strong>Patients surviving acute myocardial infarction (AMI) complicated by ventricular arrhythmias (VAs) are at high risk of early post-discharge readmissions due to multiple complications. These readmissions worsen clinical outcomes and add substantial financial strain to the U.S. healthcare system. This study investigates the prevalence, causes, and predictors of 30-day readmissions following hospitalization for AMI complicated by VAs.</p><p><strong>Methods and results: </strong>Hospitalizations for AMI complicated by VAs were identified from the 2016-2017 Nationwide Readmissions Database. Independent predictors of 30-day readmission were analyzed using multivariable survey-weighted logistic regression in the R statistical software (version 4.5.0). Among 93 588 index hospitalizations, 8154 (8.7%) resulted in 30-day readmissions. In-hospital mortality occurred in 16.43% of index admissions and 5.92% of readmissions. Significant predictors of readmission included older age (OR: 1.01; <i>P</i> < 0.001), female sex (OR: 1.13; <i>P</i> = 0.002), prior heart failure (OR: 1.28; <i>P</i> < 0.001), peripheral vascular disease (OR: 1.18; <i>P</i> = 0.002), COPD (OR: 1.43; <i>P</i> < 0.001), atrial fibrillation (OR: 1.24; <i>P</i> < 0.001), diabetes (OR: 1.29; <i>P</i> < 0.001), previous MI (OR: 1.12; <i>P</i> = 0.009), end-stage renal disease (ESRD) (OR: 1.52; <i>P</i> < 0.001), stroke (OR: 1.52; <i>P</i> < 0.001), and hospital stay >4 days (OR: 1.94; <i>P</i> < 0.001). Higher income quartiles were associated with lower readmission risk. The mean index charges were $151 722, whereas charges per readmission were $64 122.</p><p><strong>Conclusions: </strong>AMI complicated by VAs is associated with high 30-day readmission rates, driven mainly by noncardiac and select cardiac causes such as heart failure and atrial fibrillation. Enhanced monitoring of high-risk groups may improve outcomes and reduce healthcare costs.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"88 10","pages":"6321-6329"},"PeriodicalIF":1.6,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A positive Alzheimer's blood biomarker is not a diagnosis: the presence-primacy-permission framework for plasma p-tau217.","authors":"Vishal Bhatia, Adnan Khatak","doi":"10.1097/MS9.0000000000005661","DOIUrl":"https://doi.org/10.1097/MS9.0000000000005661","url":null,"abstract":"<p><p>Validated plasma phosphorylated tau 217 (p-tau217) assays identify Alzheimer disease pathology with high accuracy. Wider clinical use creates a risk of postanalytic misclassification when pathology is converted directly into a clinical diagnosis or treatment decision. This editorial examines why accuracy relative to amyloid positron emission tomography or cerebrospinal fluid biomarkers does not establish that Alzheimer disease is the principal cause of a patient's cognitive syndrome. It describes three substitutions: pathology for diagnosis, presence for primacy, and diagnosis for treatment eligibility. We propose the presence-primacy-permission framework to distinguish confirmation of pathology from clinical-biological concordance and treatment suitability. Presence requires appropriate patient selection, a validated assay, and context-specific interpretation. Primacy requires integration of cognitive phenotype, trajectory, functional status, neurologic examination, structural imaging, and coexisting pathology. Permission requires assessment of clinical stage, hemorrhagic risk, treatment feasibility, and patient goals. Separate documentation of the biomarker result, syndrome, etiologic attribution, and actionability may reduce premature diagnostic closure while preserving the clinical value of p-tau217.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"88 10","pages":"6232-6234"},"PeriodicalIF":1.6,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute mesenteric ischemia following ischemic stroke: a rare sequential embolic event managed with Ethiopia's first endovascular intervention: Retraction.","authors":"","doi":"10.1097/MS9.0000000000005724","DOIUrl":"10.1097/MS9.0000000000005724","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1097/MS9.0000000000005196.].</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"88 9","pages":"6220"},"PeriodicalIF":1.6,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13561230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Jideytro (zidesamtinib) for previously treated ros1-positive non-small cell lung cancer: a new era in post-tki therapy.","authors":"Syeda Fadak Zahra Hujjat, Md Tahmid Islam","doi":"10.1097/MS9.0000000000005662","DOIUrl":"https://doi.org/10.1097/MS9.0000000000005662","url":null,"abstract":"<p><p>ROS1-positive non-small cell lung cancer (NSCLC) is a distinct oncogene-driven subtype that commonly affects younger, never-smokers and frequently develops central nervous system metastases and kinase-domain resistance mutations. Although first- and second-generation ROS1 tyrosine kinase inhibitors (TKIs) have improved outcomes, most patients eventually progress after treatment. On 22 July 2026, the U.S. Food and Drug Administration approved Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive NSCLC previously treated with a ROS1 TKI. Zidesamtinib is a selective, brain-penetrant, macrocyclic ROS1 inhibitor that spares tropomyosin receptor kinase (TRK) signaling while maintaining activity against diverse resistance mutations, including G2032R. In the pivotal ARROS-1 trial, it produced durable responses in heavily pretreated patients, including those with brain metastases, with low treatment discontinuation. Although prospective comparisons with crizotinib, entrectinib, repotrectinib, and taletrectinib are needed, zidesamtinib represents an important addition to post-TKI therapy for ROS1-positive NSCLC.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"88 10","pages":"6229-6231"},"PeriodicalIF":1.6,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenteric vascular variations and Henle's trunk anatomy in right colon cancer surgery: implications for complete mesocolic excision and D2 lymphadenectomy.","authors":"Tarik Deflaoui, Anas Derkaoui, Rihab Amara, Hamid Ziani, Siham Nasri, Imane Skiker, Abdelali Guellil, Rachid Jabi, Mohammed Bouziane","doi":"10.1097/MS9.0000000000005637","DOIUrl":"https://doi.org/10.1097/MS9.0000000000005637","url":null,"abstract":"<p><strong>Background: </strong>Complete mesocolic excision (CME) with central lymphadenectomy represents the oncologic standard for right colon cancer surgery. However, vascular anatomical variability particularly involving the superior mesenteric vessels and Henle's gastrocolic trunk may substantially increase operative complexity and hemorrhagic risk. This study aimed to evaluate mesenteric vascular variations systematically and to analyze their implications for the quality and safety of CME/D2 right hemicolectomy.</p><p><strong>Materials and methods: </strong>A retrospective descriptive single-center study was conducted at a tertiary referral university hospital. A total of 250 consecutive patients who underwent oncologic right hemicolectomy for histologically confirmed adenocarcinoma of the right colon between January 2020 and January 2025 were included. Clinical, radiological, operative, pathological, and postoperative data were analyzed. Mesenteric vascular anatomy was evaluated using CT angiography (available in 51.2% of cases) and correlated with intraoperative observations. The study was reported according to the STROBE criteria.</p><p><strong>Results: </strong>The mean patient age was 64.5 ± 11.2 years (range 28-89) with slight female predominance (55.2%). Complicated presentations (obstruction, perforation, hemorrhage) occurred in 31.2% of cases. CT angiography was available for 128/250 patients (51.2%); its incomplete use was primarily attributable to emergency/complicated presentations (41.0% of the 122 non-angiography cases), resource/protocol constraints (34.4%), and adequate standard CT for planning (24.6%). The ileocolic and middle colic arteries were invariably present. The right colic artery was absent in 35.2% of patients, with variable origins when present. Henle's trunk was identified in 59.2% of patients, with three distinct venous configurations characterized. Open surgery was performed in 67.2% of cases. No major intraoperative vascular injury was recorded. Adequate lymph node harvest (≥12 nodes) was achieved in all patients (mean 24.6 ± 6.8 nodes). Anastomotic leakage occurred in 2.4% and 30-day mortality in 0.8%.</p><p><strong>Conclusion: </strong>Mesenteric vascular variations are the rule rather than the exception during right colon cancer surgery. Preoperative CT angiography with vascular reconstruction appears to facilitate operative planning and anatomical orientation during CME/D2 lymphadenectomy. Standardized vascular-oriented dissection may improve oncologic quality while minimizing vascular complications.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"88 10","pages":"6413-6424"},"PeriodicalIF":1.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term speech outcomes following functional palatal repair.","authors":"Anika S Szwedyc, Suvi A Alaluusua, Ville P Kinnula, Veera V Pitkänen, Anne M Saarikko","doi":"10.1097/MS9.0000000000005580","DOIUrl":"https://doi.org/10.1097/MS9.0000000000005580","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate long-term functional outcomes following palatal surgery as velopharyngeal dimensions evolve in growing children with cleft palate (CP).</p><p><strong>Summary background data: </strong>Functional palatal repair using the Furlow method effectively corrects speech symptoms related to velopharyngeal insufficiency (VPI) in patients with CP. However, existing studies have focused on short-term follow-up.</p><p><strong>Methods: </strong>This retrospective study analyzed data from 5384 participants with CP, including 92 who underwent functional palatal repair to correct speech symptoms related to VPI and were followed up until adulthood. A speech pathologist evaluated perceived velopharyngeal competence (VPC) preoperatively, postoperatively, and at long-term follow-up. Follow-up visits were scheduled at 8, 10, 12, 14, 16, and 18 years, with assessments extending up to 12 years post-surgery. We compared postoperative velopharyngeal function (VPF) at each time point.</p><p><strong>Results: </strong>A general linear mixed model and Wilcoxon signed-rank test showed no significant differences in VPF between ages 8 and 14 years. Comparison of postoperative evaluations after functional palatal repair indicated that adequate VPF was maintained in 88, 84, 82, 78, 77, and 76% at the 8-, 10-, 12-, 14-, 16-, and 18-year time points, respectively. Statistically significant negative VPF changes were observed between the 16- and 18-year time points, suggesting a progressive increase in the likelihood of VPC deterioration.</p><p><strong>Conclusion: </strong>Longitudinal follow-up after functional palatal repair showed that VPF remained adequate during growth in most patients with CP. However, during growth, some developed VPI, with a statistically significant negative change observed between 16 and 18 years of age.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"88 10","pages":"6374-6379"},"PeriodicalIF":1.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the efficacy of duloxetine and venlafaxine in chemotherapy-induced neuropathy in cancer patients: a double-blind multicenter randomized clinical trial.","authors":"Najmeh Shahini, Narges Lashkarbolouk, Saeede Khaki, Mahdi Mazandarani, Maliheh Ziaee","doi":"10.1097/MS9.0000000000005428","DOIUrl":"https://doi.org/10.1097/MS9.0000000000005428","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced peripheral neuropathy is a common non-hematologic complication and a major dose-limiting factor in cancer treatment, potentially reducing patient survival. Duloxetine and venlafaxine, antidepressant drugs, have demonstrated efficacy in managing neuropathic pain associated with diabetes and fibromyalgia in several studies.</p><p><strong>Methods: </strong>In this randomized, double-blind clinical trial, cancer patients undergoing chemotherapy were assessed for neuropathy and pain using the Patient Neurotoxicity Questionnaire and McGill Pain Questionnaire at baseline, 6 weeks, and 12 weeks. Patients were randomized to receive either duloxetine (Group A: 30 mg daily, increasing to 60 mg daily after 1 week), venlafaxine (Group B: 37.5 mg daily, increasing to 75 mg daily after 1 week), or a placebo (Group C).</p><p><strong>Results: </strong>Among 141 randomized patients (61% female; mean age 64.4 years), no significant difference in pain scores was observed between groups at the primary endpoint of week 6 (<i>P</i> = 0.59). At the secondary endpoint of week 12, a statistically significant difference between groups emerged (<i>P</i> = 0.03), driven by a reduction in pain scores in the duloxetine group compared with placebo (<i>post hoc P</i> = 0.03). Within-group reductions were significant for both duloxetine (<i>P</i> = 0.002) and venlafaxine (<i>P</i> = 0.007) at 12 weeks.</p><p><strong>Conclusion: </strong>This trial did not meet its primary endpoint at 6 weeks with duloxetine or venlafaxine compared to placebo. Secondary analyses at 12 weeks suggest that only duloxetine may provide clinically meaningful symptom relief. Venlafaxine findings remain inconclusive, as within-group improvements did not translate into statistically significant between-group superiority.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"88 10","pages":"6262-6271"},"PeriodicalIF":1.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case report: atypical presentation of Klinefelter syndrome in a 24-year-old male at suburban tertiary care hospital in Nepal.","authors":"Bhawana Bastola, Barada Bajracharya, Abhyuday Kumar Yadav, Rajendra Tamrakar","doi":"10.1097/MS9.0000000000005608","DOIUrl":"https://doi.org/10.1097/MS9.0000000000005608","url":null,"abstract":"<p><p>Klinefelter syndrome (KS) is the most common chromosomal condition affecting males, usually caused by the presence of an extra X chromosome (47, XXY). However, it often remains undiagnosed until adulthood. We report a unique case of a 24-year-old man whose primary concern was persistent nausea and vomiting, an atypical presenting complaint of Klinefelter syndrome. Further evaluation revealed typical features of KS, including infertility despite normal sexual desire, gradual enlargement of the breasts, tall stature, sparse facial and body hair, small testes, and learning difficulties. An uncommon finding in the patient was premature loss of dentition. Hormonal tests showed low testosterone levels with elevated gonadotropins and estradiol, consistent with primary hypogonadism, and karyotype analysis confirmed the diagnosis. This case highlights the wide spectrum of clinical features associated with Klinefelter syndrome, including both typical and atypical manifestations. This report emphasizes the need for increased awareness of such unusual presentations, for early diagnosis, and a multidisciplinary approach to management that can improve physical health, psychological well-being, and overall quality of life.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"88 10","pages":"6807-6811"},"PeriodicalIF":1.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Left ventricular thrombus formation in paraganglioma: a rare but serious complication - a case report.","authors":"Abdulrahman Alsbikhan, Hrag Altounian, Edward Marashly, Adonis Jabbour, Salim Haddad, Maria Fares, Mahdi Kawar","doi":"10.1097/MS9.0000000000005621","DOIUrl":"https://doi.org/10.1097/MS9.0000000000005621","url":null,"abstract":"<p><strong>Introduction and importance: </strong>The incidence rate of paraganglioma stands at approximately 1 case per 300 000 person-years. Symptoms resembling anxiety and panic attacks are prevalent within the general populace, rendering the identification of individuals afflicted with pheochromocytoma or paraganglioma a formidable task for healthcare practitioners.</p><p><strong>Case presentation: </strong>A 43-year-old presented with ischemic signs that turned into necrosis at his left foot due to diffused thrombosis in his main arteries, furthermore Echodiagram indicated the presence of left ventricular thrombosis, through which the diagnosis of paraganglioma was made and confirmed through histological examination.</p><p><strong>Clinical discussion: </strong>Paragangliomas are rare tumors originating from extra-adrenal chromaffin cells, typically found in areas such as the carotid body and aortic arch. These tumors can cause cardiovascular issues like hypertension, tachycardia, and thrombus formation. In this case, a paraganglioma was detected below the renal arteries, an uncommon location, with extensive arterial and left ventricular thrombi. Paragangliomas induce a hypercoagulable state due to catecholamine excess, vasospasm, and vascular compression, as seen in this patient, who had thrombi in the lower extremities and aortic artery, increasing embolization risks. Diagnosis involves clinical evaluation, biochemical testing, and imaging studies, with surgical resection as the primary treatment. Preoperative management focuses on controlling blood pressure and glucose, while postoperative care includes anticoagulation therapy. This case highlights the multifaceted vascular complications of paragangliomas, emphasizing the need for a comprehensive diagnostic and treatment approach.</p><p><strong>Conclusion: </strong>Increasing follow-up sessions with this patient to prevent recurring issues, including the consideration of coronary vascular imaging and administrating anti-coagulant drugs.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"88 10","pages":"6747-6752"},"PeriodicalIF":1.6,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of body mass index on operative efficiency and outcomes in parathyroid surgery.","authors":"Nicholas A O'Keeffe, Freya Timon, Niall McInerney, Andreea Nae, Conrad Timon","doi":"10.1097/MS9.0000000000005623","DOIUrl":"https://doi.org/10.1097/MS9.0000000000005623","url":null,"abstract":"<p><strong>Objectives: </strong>The relationship between obesity and surgical outcomes is well described in major operations, but its influence on contemporary parathyroidectomy remains uncertain. This study evaluated the impact of raised body mass index (BMI) on operative efficiency, preoperative biochemistry, localization imaging, and perioperative outcomes in a single-surgeon cohort.</p><p><strong>Methods: </strong>We retrospectively reviewed all parathyroidectomies performed by a single surgeon between September 2019 and September 2023. Patient demographics, BMI, operative duration, preoperative localization imaging, serum calcium and parathyroid hormone (PTH), length of stay, and complications were analyzed. Patients were classified as normal weight, overweight, or obese according to World Health Organization definitions. Continuous variables were compared using one-way ANOVA and categorical variables using chi-squared or Fisher's exact tests. Multivariate linear regression including age, sex, BMI category, operative extent and localization status identified independent predictors of operative time (p<0.05).</p><p><strong>Results: </strong>Among 225 patients (81.3% female; mean age 58 years), 39.6% were normal weight, 36.0% overweight, and 24.4% obese. Mean operative time was longer in obese patients (50.9 minutes) compared with normal weight (35.8 minutes) and overweight (35.5 minutes) groups (<i>P</i> < 0.001). Obese patients had higher preoperative PTH (<i>P</i> = 0.022), with no significant differences in serum calcium, localization imaging success, length of stay, cure rates, or complication rates.</p><p><strong>Conclusions: </strong>Obesity was independently associated with prolonged operative time and higher preoperative PTH in patients undergoing parathyroidectomy, without an increase in complications or length of stay.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":"88 10","pages":"6258-6261"},"PeriodicalIF":1.6,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}